Global Aptamers Market Size, Share, Growth Analysis, By Type(Nucleic Acid and Peptide), By Application(Diagnostics, Therapeutics) - Industry Forecast 2024-2031

Global Aptamers Market size was valued at USD 1.20 billion in 2022 and is poised to grow from USD 1.43 billion in 2023 to USD 5.83 billion by 2031, at a CAGR of 19.2% during the forecast period (2024-2031).

To increase their market share, major players are using tactics including product modification, new product approval, mergers and acquisitions, and geographical growth. These methods are all aimed at improving their current products. Applications of aptamers in therapeutics may find new growth opportunities as a result of such activities. 'NeoVentures Biotechnology Inc. (United States)', 'Base Pair Biotechnologies, Inc. (United States)', 'Aptagen, LLC (United States)', 'SomaLogic, Inc. (United States)', 'Vivonics, Inc. (United States)', 'Aptamer Sciences, Inc. (United States)', 'TriLink BioTechnologies, LLC (United States)', 'AMS Biotechnology Europe Ltd. (United Kingdom)', 'Aptamer Group Ltd. (United Kingdom)', 'NOXXON Pharma AG (Germany)', 'AM Biotechnologies, LLC (United States)', 'Aptus Biotech S.L. (Spain)', 'Aptamer Group (United Kingdom)', 'Ophthotech Corporation (United States)', 'Vivonics, Inc. (United States)', 'ATDBio Ltd. (United Kingdom)', 'Base Pair Biotechnologies, Inc. (United States)', 'Am Biotechnologies, LLC (United States)', 'Aptamer Sciences, Inc. (United States)', 'Orla Protein Technologies Ltd. (United Kingdom)', 'Archemix Corp. (United States)', 'AptaMatrix (United States)'

Aptamers play a crucial role in personalized medicine as they can specifically bind to target molecules, including proteins, peptides, and small molecules. The growing emphasis on targeted therapies and precision medicine has led to increased demand for aptamers as they offer advantages such as high specificity, low immunogenicity, and customizable properties. Aptamers enable precise molecular recognition, facilitating the development of personalized treatment strategies.

Focus on SELEX Optimization and Automation : SELEX (Systematic Evolution of Ligands by Exponential Enrichment) is the primary method for aptamer selection. There is a growing focus on optimizing and automating the SELEX process to enhance efficiency, reduce costs, and improve aptamer quality. Advances in high-throughput screening, microfluidics, and robotics are being employed to streamline the aptamer development process, making it more accessible and scalable.

With a market share of 44.48% in 2023, North America region led the aptamers market. The rising incidence of chronic diseases, the region's robust healthcare system, and the growing interest of research labs in the field of aptamers are some of the main drivers of the area's supremacy. Also in April 2022, Noxxon Pharma made the announcement that it would disclose top line results for its NOX-A12 GLORIA study in brain cancer at the annual meeting of the American Society of Clinical Oncology.